Dry eye is common in children with JRA

Article

Dry eye is common in children with juvenile rheumatoid arthritis (JRA).

Dry eye is common in children with juvenile rheumatoid arthritis (JRA), reveals an investigation in the European Journal of Ophthalmology.

Dr Amany Abdel-Fattah El-Shazly et al., Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, conducted an evaluation into dry eye on 40 patients with JRA.

The study consisted of 28 girls and 12 boys between the ages of 7 and 12 years. Each patient underwent medical history, clinical examination and a full ophthalmologic evaluation.

Tear filrm break-up time, Schirmer-1 test and corneal fluorescein staining were to test for dry eye. The control gropu consisted of 20 healthy age and sex-matched children.

The results demonstrated that 30 patients presented with consistent findings with dry eye diagnosis. First-degree dryness was found in 20 patients, second-degree dryness in 8 patients and 2 had third-degree dryness.

Dry eye severity tended to be significantly lower in remission, compared to amount of disease activity. The only factor that seemed to affect dry eye parameters was the duration of the disease.

The study authors suggest that all children with JRA should be screened for dry eye as the severity of dry eye is highly correlated with disease activity.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.